γδ T cell immune manipulation during chronic phase of simian HIV infection confers immunological benefits

Journal of Immunology

Volumn 183, Issue 8, 2009, Pages 5407-5417

  Ali, Zahida ^a   Yan, Lin ^a   Plagman, Nicholas ^b   Reichenberg, Armin ^c   Hintz, Martin ^c   Jomaa, Hassan ^c   Villinger, Francois ^b   Chen, Zheng W ^a  

^a UNIVERSITY OF ILLINOIS   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL GIESSEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXY 3 METHYLBUT 2 ENYL PYROPHOSPHATE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; RECOMBINANT INTERLEUKIN 2; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS ANTIGEN; 4 HYDROXY 3 METHYL 2 BUTENYL DIPHOSPHATE; 4-HYDROXY-3-METHYL-2-BUTENYL DIPHOSPHATE; INTERLEUKIN 2; LYMPHOCYTE ANTIGEN RECEPTOR; ORGANOPHOSPHATE; VIRUS ANTIBODY; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ACUTE DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY PRODUCTION; ANTIBODY TITER; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELLULAR IMMUNITY; CHRONIC DISEASE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE COURSE; DISEASE EXACERBATION; DRUG POTENCY; EFFECTOR CELL; GAMMA DELTA T LYMPHOCYTE; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MONOTHERAPY; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RHESUS MONKEY; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS ENVELOPE; VIRUS LOAD; ANIMAL; BLOOD; DRUG EFFECT; IMMUNOLOGY; MACACA MULATTA; METABOLISM; TRANSPLANTATION;

ANIMALS; ANTIBODIES, VIRAL; CHRONIC DISEASE; INTERFERON-GAMMA; INTERLEUKIN-2; MACACA MULATTA; PHOSPHORIC ACID ESTERS; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; RNA, VIRAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA; VIRAL LOAD;

EID: 77954123620     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.0901760     Document Type: Article

References (53)

1. Buchbinder, S. P., D. V. Mehrotra, A. Duerr, D. W. Fitzgerald, R. Mogg, D. Li, P. B. Gilbert, J. R. Lama, M. Marmor, C. Del Rio, et al. 2008. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 372: 1881-1893.
2. McElrath, M. J., S. C. De Rosa, Z. Moodie, S. Dubey, L. Kierstead, H. Janes, O. D. Defawe, D. K. Carter, J. Hural, R. Akondy, et al. 2008. HIV-1 vaccineinduced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 372: 1894-1905.
3. + T cells and anti-microbial immune responses. Microbes Infect. 5: 491-498.
4. Corvaisier, M., A. Moreau-Aubry, E. Diez, J. Bennouna, J. F. Mosnier, E. Scotet, M. Bonneville, and F. Jotereau. 2005. Vγ9Vδ2 T cell response to colon carcinoma cells. J. Immunol. 175: 5481-5488.
5. McClanahan, J., P. I. Fukushima, and M. Stetler-Stevenson. 1999. Increased peripheral blood γδ T-cells in patients with lymphoid neoplasia: a diagnostic dilemma in flow cytometry. Cytometry 38: 280-285.
6. Hintz, M., A. Reichenberg, B. Altincicek, U. Bahr, R. M. Gschwind, A. K. Kollas, E. Beck, J. Wiesner, M. Eberl, and H. Jomaa. 2001. Identification of (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphate as a major activator for human γδ T cells in Escherichia coli. FEBS Lett. 509: 317-322.
7. Tanaka, Y., C. T. Morita, Y. Tanaka, E. Nieves, M. B. Brenner, and B. R. Bloom. 1995. Natural and synthetic non-peptide antigens recognized by human γδ T cells. Nature 375: 155-158.
8. Altincicek, B., J. Moll, N. Campos, G. Foerster, E. Beck, J. F. Hoeffler, C. Grosdemange-Billiard, M. Rodriguez-Concepcion, M. Rohmer, A. Boronat, et al. 2001. Cutting edge: human γδ T cells are activated by intermediates of the 2-C-methyl-D-erythritol 4-phosphate pathway of isoprenoid biosynthesis. J. Immunol. 166: 3655-3658.
9. Eberl, M., M. Hintz, A. Reichenberg, A. K. Kollas, J. Wiesner, and H. Jomaa. 2003. Microbial isoprenoid biosynthesis and human γδ T cell activation. FEBS Lett. 544: 4-10.
10. Eberl, M., M. Hintz, Z. Jamba, E. Beck, H. Jomaa, and G. Christiansen. 2004. Mycoplasma penetrans is capable of activating Vγ9/Vβ2 T cells while other human pathogenic mycoplasmas fail to do so. Infect. Immun. 72: 4881-4883.
11. Zhang, Y., Y. Song, F. Yin, E. Broderick, K. Siegel, A. Goddard, E. Nieves, L. Pasa-Tolic, Y. Tanaka, H. Wang, et al. 2006. Structural studies of Vγ2Vδ2 T cell phosphoantigens. Chem. Biol. 13: 985-992.
12. Gober, H. J., M. Kistowska, L. Angman, P. Jeno, L. Mori, and G. De Libero. 2003. Human T cell receptor γδ cells recognize endogenous mevalonate metabolites in tumor cells. J. Exp. Med. 197: 163-168.
13. Bonneville, M., and J. J. Fournie. 2005. Sensing cell stress and transformation through Vγ9Vδ2 T cell-mediated recognition of the isoprenoid pathway metabolites. Microbes Infect. 7: 503-509.
14. Poccia, F., B. Cipriani, S. Vendetti, V. Colizzi, Y. Poquet, L. Battistini, M. Lopez-Botet, J. J. Fournie, and M. L. Gougeon. 1997. CD94/NKG2 inhibitory receptor complex modulates both anti-viral and anti-tumoral responses of polyclonal phosphoantigen-reactive Vγ9Vδ2 T lymphocytes. J. Immunol. 159: 6009-6017. (Pubitemid 127471537)
15. Gan, Y. H., and M. Malkovsky. 1996. Mechanisms of simian γδ T cell cytotoxicity against tumor and immunodeficiency virus-infected cells. Immunol. Lett. 49: 191-196.
16. Poccia, F., L. Battistini, B. Cipriani, G. Mancino, F. Martini, M. L. Gougeon, and V. Colizzi. 1999. Phosphoantigen-reactive Vγ9Vδ2 T lymphocytes suppress in vitro human immunodeficiency virus type 1 replication by cell-released antiviral factors including CC chemokines. J. Infect. Dis. 180: 858-861.
17. Poccia, F., C. Agrati, F. Martini, M. R. Capobianchi, M. Wallace, and M. Malkovsky. 2005. Antiviral reactivities of γδ T cells. Microbes Infect. 7: 518-528.
18. Devilder, M. C., S. Maillet, I. Bouyge-Moreau, E. Donnadieu, M. Bonneville, and E. Scotet. 2006. Potentiation of antigen-stimulated Vγ9Vδ2 T cell cytokine production by immature dendritic cells (DC) and reciprocal effect on DC maturation. J. Immunol. 176: 1386-1393. (Pubitemid 43134280)
19. Brandes, M., K. Willimann, and B. Moser. 2005. Professional antigen-presentation function by human γδ T cells. Science 309: 264-268.
20. + αβ T cell responses. Proc. Natl. Acad. Sci. USA 106: 2307-2312.
21. Brandes, M., K. Willimann, A. B. Lang, K. H. Nam, C. Jin, M. B. Brenner, C. T. Morita, and B. Moser. 2003. Flexible migration program regulates γδT-cell involvement in humoral immunity. Blood 102: 3693-3701.
22. Caccamo, N., L. Battistini, M. Bonneville, F. Poccia, J. J. Fournie, S. Meraviglia, G. Borsellino, R. A. Kroczek, C. La Mendola, E. Scotet, et al. 2006. CXCR5 identifies a subset of Vγ9Vδ2 T cells which secrete IL-4 and IL-10 and help B cells for antibody production. J. Immunol. 177: 5290-5295.
23. + T cells during mycobacterial infections. Science 295: 2255-2258.
24. Wang, L., A. Kamath, H. Das, L. Li, and J. F. Bukowski. 2001. Antibacterial effect of human Vγ9Vδ2 T cells in vivo. J. Clin. Invest. 108: 1349-1357.
25. Dieli, F., M. Troye-Blomberg, J. Ivanyi, J. J. Fournie, M. Bonneville, M. A. Peyrat, G. Sireci, and A. Salerno. 2000. Vγ9Vδ2 T lymphocytes reduce the viability of intracellular Mycobacterium tuberculosis. Eur. J. Immunol. 30: 1512-1519.
26. Farouk, S. E., L. Mincheva-Nilsson, A. M. Krensky, F. Dieli, and M. Troye-Blomberg. 2004. γδT cells inhibit in vitro growth of the asexual blood stages of Plasmodium falciparum by a granule exocytosis-dependent cytotoxic pathway that requires granulysin. Eur. J. Immunol. 34: 2248-2256.
27. Troye-Blomberg, M., S. Worku, P. Tangteerawatana, R. Jamshaid, K. Soderstrom, G. Elghazali, L. Moretta, M. Hammarstrom, and L. Mincheva-Nilsson. 1999. Human γδ T cells that inhibit the in vitro growth of the asexual blood stages of the Plasmodium falciparum parasite express cytolytic and proinflammatory molecules. Scand. J. Immunol. 50: 642-650.
28. + cells expressing the Jγ1.2 segment. AIDS Res. Hum. Retroviruses 19: 21-29.
29. Li, H., H. Peng, P. Ma, Y. Ruan, B. Su, X. Ding, C. Xu, C. D. Pauza, and Y. Shao. 2008. Association between Vγ9Vδ2 T cells and disease progression after infection with closely related strains of HIV in China. Clin. Infect. Dis. 46: 1466-1472.
30. Poccia, F., S. Boullier, H. Lecoeur, M. Cochet, Y. Poquet, V. Colizzi, J. J. Fournie, and M. L. Gougeon. 1996. Peripheral Vγ9Vδ2 T cell deletion and anergy to nonpeptidic mycobacterial antigens in asymptomatic HIV-1-infected persons. J. Immunol. 157: 449-461.
31. Kosub, D. A., G. Lehrman, J. M. Milush, D. Zhou, E. Chacko, A. Leone, S. Gordon, G. Silvestri, J. G. Else, P. Keiser, et al. 2008. γ/δ T-cell functional responses differ after pathogenic human immunodeficiency virus and nonpathogenic simian immunodeficiency virus infections. J. Virol. 82: 1155-1165.
32. + T-cell responses during active mycobacterial coinfection of simian immunodeficiency virus SIVmac-infected monkeys. J. Virol. 77: 2998-3006.
33. Martini, F., F. Poccia, D. Goletti, S. Carrara, D. Vincenti, G. D'Offizi, C. Agrati, G. Ippolito, V. Colizzi, L. P. Pucillo, and C. Montesano. 2002. Acute human immunodeficiency virus replication causes a rapid and persistent impairment of Vγ9Vδ2 T cells in chronically infected patients undergoing structured treatment interruption. J. Infect. Dis. 186: 847-850.
34. Hebbeler, A. M., N. Propp, C. Cairo, H. Li, J. S. Cummings, L. P. Jacobson, J. B. Margolick, and C. D. Pauza. 2008. Failure to restore the Vγ2-Jβ1.2 repertoire in HIV-infected men receiving highly active antiretroviral therapy (HAART). Clin. Immunol. 128: 349-357.
35. + T cells. J. Infect. Dis. 190: 1438-1447.
36. Bordon, J., P. S. Evans, N. Propp, C. E. Davis, Jr., R. R. Redfield, and C. D. Pauza. 2004. Association between longer duration of HIV-suppressive therapy and partial recovery of the Vγ2 T cell receptor repertoire. J. Infect. Dis. 189: 1482-1486.
37. Ali, Z., L. Shao, L. Halliday, A. Reichenberg, M. Hintz, H. Jomaa, and Z. W. Chen. 2007. Prolonged (E)-4-hydroxy-3-methyl-but-2-enyl pyrophosphatedriven antimicrobial and cytotoxic responses of pulmonary and systemic Vγ9Vδ2 T cells in macaques. J. Immunol. 179: 8287-8296.
38. Huang, D., C. Y. Chen, Z. Ali, L. Shao, L. Shen, H. A. Lockman, R. E. Barnewall, C. Sabourin, J. Eestep, A. Reichenberg, et al. 2009. Antigenspecific Vγ9Vδ2 T effector cells confer homeostatic protection against pneumonic plaque lesions. Proc. Natl. Acad. Sci. USA 106: 7553-7558.
39. Reimann, K. A., J. T. Li, R. Veazey, M. Halloran, I. W. Park, G. B. Karlsson, J. Sodroski, and N. L. Letvin. 1996. A chimeric simian/human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate env causes an AIDS-like disease after in vivo passage in rhesus monkeys. J. Virol. 70: 6922-6928. (Pubitemid 26307405)
40. + T cell depeletion and viral replication in SIV infection. Science 280: 427-431.
41. Amara, R. R., F. Villinger, J. D. Altman, S. L. Lydy, S. P. O'Neil, S. I. Staprans, D. C. Montefiori, Y. Xu, J. G. Herndon, L. S. Wyatt, et al. 2001. Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292: 69-74.
42. Cline, A. N., J. W. Bess, M. Piatak, Jr., and J. D. Lifson. 2005. Highly sensitive SIV plasma viral load assay: practical considerations, realistic performance expectations, and application to reverse engineering of vaccines for AIDS. J. Med. Primatol. 34: 303-312.
43. Matsushita, S., M. Robert-Guroff, J. Rusche, A. Koito, T. Hattori, H. Hoshino, K. Javaherian, K. Takatsuki, and S. Putney. 1988. Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 62: 2107-2114.
44. Putney, S. D., T. J. Matthews, W. G. Robey, D. L. Lynn, M. Robert-Guroff, W. T. Mueller, A. J. Langlois, J. Ghrayeb, S. R. Petteway, Jr., K. J. Weinhold, et al. 1986. HTLV-III/LAV-neutralizing antibodies to an E. coli-produced fragment of the virus envelope. Science 234: 1392-1395. (Pubitemid 17210218)
45. Rusche, J. R., D. L. Lynn, M. Robert-Guroff, A. J. Langlois, H. K. Lyerly, H. Carson, K. Krohn, A. Ranki, R. C. Gallo, D. P. Bolognesi, et al. 1987. Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc. Natl. Acad. Sci. USA 84: 6924-6928.
46. Brenchley, J. M., D. A. Price, T. W. Schacker, T. E. Asher, G. Silvestri, S. Rao, Z. Kazzaz, E. Bornstein, O. Lambotte, D. Altmann, et al. 2006. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12: 1365-1371.
47. + T lymphocytes. J. Immunol. 174: 4753-4760.
48. Davey, R. T., Jr., D. G. Chaitt, J. M. Albert, S. C. Piscitelli, J. A. Kovacs, R. E. Walker, J. Falloon, M. A. Polis, J. A. Metcalf, H. Masur, et al. 1999. A randomized trial of high- versus low-dose subcutaneous interleukin-2 outpatient therapy for early human immunodeficiency virus type 1 infection. J. Infect. Dis. 179: 849-858.
49. + T lymphocytes in naive and simian immunodeficiency virus-infected Rhesus monkeys. AIDS Res. Hum. Retroviruses 17: 873-886.
50. Beq, S., M. T. Nugeyre, R. Ho Tsong Fang, D. Gautier, R. Legrand, N. Schmitt, J. Estaquier, F. Barre-Sinoussi, B. Hurtrel, R. Cheynier, and N. Israel. 2006. IL-7 induces immunological improvement in SIV-infected rhesus macaques under antiviral therapy. J. Immunol. 176: 914-922.
51. Picker, L. J., E. F. Reed-Inderbitzin, S. I. Hagen, J. B. Edgar, S. G. Hansen, A. Legasse, S. Planer, M. Piatak, Jr., J. D. Lifson, V. C. Maino, et al. 2006. IL-15 induces CD4 effector memory T cell production and tissue emigration in nonhuman primates. J. Clin. Invest. 116: 1514-1524.
52. + T cell responses. J. Immunol. 180: 350-360.
53. Sawai, E. T., M. S. Hamza, M. Ye, K. E. Shaw, and P. A. Luciw. 2000. Pathogenic conversion of live attenuated simian immunodeficiency virus vaccines is associated with expression of truncated Nef. J. Virol. 74: 2038-2045.